TB-500 is a synthetic version of a peptide fragment derived from Thymosin Beta-4, a naturally occurring protein involved in actin regulation and cell migration.
🔬 Studied for: Wound & Tissue Repair Research
💊 Also studied for: Cardiac & Vascular Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
TB-500 is a synthetic version of a peptide fragment derived from Thymosin Beta-4, a naturally occurring protein involved in actin regulation and cell migration. It is frequently studied alongside BPC-157 in tissue-repair and regenerative-research literature.
TB-500 is a fragment of the actin-binding protein Thymosin Beta-4. Research suggests it may influence cell migration, angiogenesis, and the formation of new blood vessels and muscle fibers, which are the mechanisms most commonly cited in wound-healing and cardiac-repair studies.
These are effects TB-500 (Thymosin Beta-4) has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
Preclinical studies have investigated Thymosin Beta-4 fragments for their potential role in accelerating dermal wound closure and skeletal-muscle repair through effects on cell migration and angiogenesis.
A portion of the Thymosin Beta-4 literature has examined its effects in animal models of cardiac injury, where researchers have investigated its role in supporting vascular formation and reducing scar tissue after ischemic injury.
Doses reported in animal studies vary widely by model and body weight and do not translate to an established human dose. No clinically approved human dosage exists for TB-500.
Compound X does not provide dosing recommendations. TB-500 (Thymosin Beta-4) is sold for laboratory research use only and is not intended for human consumption.
Human safety data for TB-500 is limited, as it is not FDA-approved and has not completed large-scale human trials. Reported concerns in available reports include injection-site reactions and transient fatigue; long-term human safety remains uncharacterized.
No. TB-500 (Thymosin Beta-4) is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Wound & Tissue Repair Research — Preclinical studies have investigated Thymosin Beta-4 fragments for their potential role in accelerating dermal wound closure and skeletal-muscle repair through effects on cell migration and angiogenesis.
In the US, UK, Canada and Australia, TB-500 (Thymosin Beta-4) is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
Peer-reviewed Thymosin Beta-4 research is indexed on PubMed under search terms such as "Thymosin Beta-4 wound healing" and "TB-500 tissue repair."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.